Rabeximod - PGK1 inhibitor for renal fibrosis and inflammation.
Our mission
Renity Pharma is committed to redefining care for inflammatory and fibrotic kidney diseases through the development of a safe, targeted fibrosis therapy.
Rabeximod is a highly selective PGK1 inhibitor.
Rabeximod specific properties enable selective inhibition of fibrosis-driver inflammatory mechanisms.
Innovation Overview
Excellent clinical safety from 300+ patients in inflammatory indication.
Repositioning the molecule for renal indications based on novel non-clinical evidence.